Who are A3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, Cozaar, VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE, Candemore tablet, Aliskiren + Valsartan, Valsartan/aliskiren.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/a3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

A3 — Competitive Intelligence Brief

A3 (A3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin receptor blocker. Area: Cardiovascular.

marketed Angiotensin receptor blocker AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

A3 (A3) — Breath of Life International Pharma Ltd. A3 is a medication that works by inhibiting the renin-angiotensin system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
A3 TARGET	A3	Breath of Life International Pharma Ltd	marketed	Angiotensin receptor blocker	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE	Novartis	marketed	Angiotensin II receptor blocker (ARB) + thiazide diuretic	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter (NCC)
Candemore tablet	Candemore tablet	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Aliskiren + Valsartan	Aliskiren + Valsartan	HeartDrug Research LLC	marketed	Direct renin inhibitor + angiotensin II receptor blocker combination	Renin and AT1 receptor
Valsartan/aliskiren	Valsartan/aliskiren	Novartis	marketed	Angiotensin II receptor blocker + direct renin inhibitor combination	AT1 receptor (valsartan); renin (aliskiren)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin receptor blocker class)

Asan Medical Center · 1 drug in this class
Breath of Life International Pharma Ltd · 1 drug in this class
National University of Ireland, Galway, Ireland · 1 drug in this class
Rambam Health Care Campus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). A3 — Competitive Intelligence Brief. https://druglandscape.com/ci/a3. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab